Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Asthma, Inflammation and G Protein-coupled Receptors (GPCR)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2013 by University Hospital, Strasbourg, France
Sponsor:
Collaborator:
National Research Agency, France
Information provided by (Responsible Party):
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT00793676
First received: November 17, 2008
Last updated: June 7, 2013
Last verified: June 2013

November 17, 2008
June 7, 2013
September 2008
May 2014   (final data collection date for primary outcome measure)
differential expression of GPCRs [ Time Frame: 1 day ] [ Designated as safety issue: No ]
differencial expression of GPCRs [ Time Frame: 1 day ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00793676 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Asthma, Inflammation and G Protein-coupled Receptors (GPCR)
G Protein Coupled Receptor (GPCR)Signature as Biomarker of Chronic Pulmonary Inflammatory Diseases and of Therapeutic Follow-up

The G protein-coupled receptors (GPCRs) are a family of proteins expressed at the cell membrane. They are composed of 380 members involved in the important functions of the organism and are privileged therapeutic targets.Their expression is highly modulated depending on the metabolic state of the cells, in particular in pathological situations.our study proposes to determine whether GPCR expression modulation could be used as a biomarker, either prognostic or diagnostic, of treatments.To do so , the investigators will determine the expression profile of the 380 human GPCRs in human blood cell samples in two chronic inflammatory pulmonary diseases : asthma and COPD (chronic obstructive pulmonary disease ) . These have opposed inflammatory infiltrates : asthma is associated with eosinophil and Th2 lymphocyte infiltration whereas COPD shows neutrophils and macrophages within the airways with a Th1 lymphocytic population. The GPCR signature (transcriptomic) will be determined on total white blood cells as well as on isolated mono- and poly-nuclear populations obtained from healthy subjects and patients selected at the asthma or COPD consultation. The expression profiling analysis will reveal sub-groups of GPCRs whose expression is modified in disease. The specificity of the variation of expression of these biomarker sub-populations will be determined, by a study recruiting a hundred patients and controls per disease on this restraint number of genes. The outcomes of the project will lead to establish GPCR "identity cards" for these chronic inflammatory diseases, which might therefore be used as diagnostic or prognostic biomarkers to follow the evolution of a disease or the efficacy of a given treatment. In addition, detailed analysis of the identified GPCRs will lead to propose new therapeutic targets for inflammatory diseases. This study has therefore the objective of validating GPCRs as potential biomarkers for inflammatory diseases.

Multicentre non-randomized

Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Asthma
  • COPD
  • Other: spirometry
  • Other: blood test
  • A= Asthma
    Interventions:
    • Other: spirometry
    • Other: blood test
  • B= COPD
    Intervention: Other: blood test
  • C= Control
    Intervention: Other: blood test
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
310
October 2014
May 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Asthma group
  • COPD group
  • Control group

Exclusion Criteria:

  • Patients with infection or inflammatory diseases
Both
18 Years to 85 Years
Yes
Contact: Romain Kessler, MD 0369550377 ext 0033 romain.kessler@chru-strasbourg.fr
France
 
NCT00793676
4171
No
University Hospital, Strasbourg, France
University Hospital, Strasbourg, France
National Research Agency, France
Principal Investigator: Romain Kessler, MD University Hospital, Strasbourg, France
University Hospital, Strasbourg, France
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP